Doshi Rajkumar, Shah Priyank, Meraj Perwaiz M
Department of Cardiology, North Shore University Hospital, Northwell Health, Manhasset, New York.
Department of Cardiology, Medical College of Georgia-Southwest Clinical Campus, Albany, Georgia.
Clin Cardiol. 2018 Mar;41(3):326-332. doi: 10.1002/clc.22866. Epub 2018 Mar 24.
Transcatheter aortic valve replacement (TAVR) is the preferred option for high-risk patients with severe aortic stenosis. The preferred access for TAVR is transfemoral (TF). Alternatives include the transapical (TA), trans-subclavian (TS), and direct aortic (TAo) approaches.
The TF approach is associated with lower in-hospital outcomes as well as shorter length of stay and lower cost of hospitalization.
The National Inpatient Sample database from 2012 through 2014 was used to obtain the TAVR study population. International Classification of Diseases, 9th Revision, Clinical Modification procedure codes were utilized to identify the 2 groups. In-hospital outcomes were compared in propensity-score-matched (1:3) cohorts, in which we took TA-TAVR as a control.
A total of 8210 (weighted N = 41 050) patients were identified. Of these, 1622 (weighted N = 8110) patients underwent TA-TAVR and 6588 (weighted N = 32 940) patients underwent TF-TAVR. In-hospital mortality was lower with TF-TAVR (4% vs 5.4%; P = 0.0355), along with a shorter length of stay (7.7 vs 9.7 days; P < 0.0001) and lower median hospitalization cost ($64 216 vs $74 735; P < 0.0001). Secondary outcomes of acute renal failure, transfusion, cardiogenic shock, and composite of all complications were lower with TF-TAVR.
TF-TAVR is safer and associated with lower in-hospital outcomes compared with TA-TAVR and should be the preferred approach. As TAVR is gaining popularity in intermediate- and low-risk patients, we must not lose sight of the serious mortality and secondary outcomes associated with TA-TAVR access.
经导管主动脉瓣置换术(TAVR)是高危重度主动脉瓣狭窄患者的首选治疗方案。TAVR的首选入路是经股动脉(TF)。其他入路包括经心尖(TA)、经锁骨下动脉(TS)和直接主动脉(TAo)入路。
TF入路与较低的院内结局、较短的住院时间和较低的住院费用相关。
使用2012年至2014年的国家住院患者样本数据库获取TAVR研究人群。利用国际疾病分类第九版临床修订版程序代码识别这两组患者。在倾向评分匹配(1:3)队列中比较院内结局,其中我们将TA-TAVR作为对照。
共识别出8210例(加权N = 41050)患者。其中,1622例(加权N = 8110)患者接受了TA-TAVR,6588例(加权N = 32940)患者接受了TF-TAVR。TF-TAVR的院内死亡率较低(4%对5.4%;P = 0.0355),住院时间较短(7.7天对9.7天;P < 0.0001),住院费用中位数较低(64216美元对74735美元;P < 0.0001)。TF-TAVR的急性肾衰竭、输血、心源性休克以及所有并发症的综合次要结局较低。
与TA-TAVR相比,TF-TAVR更安全且与较低的院内结局相关,应作为首选入路。由于TAVR在中低风险患者中越来越受欢迎,我们绝不能忽视与TA-TAVR入路相关的严重死亡率和次要结局。